[go: up one dir, main page]

WO2013038119A2 - Device for storing and dispensing liquid - Google Patents

Device for storing and dispensing liquid Download PDF

Info

Publication number
WO2013038119A2
WO2013038119A2 PCT/FR2012/052079 FR2012052079W WO2013038119A2 WO 2013038119 A2 WO2013038119 A2 WO 2013038119A2 FR 2012052079 W FR2012052079 W FR 2012052079W WO 2013038119 A2 WO2013038119 A2 WO 2013038119A2
Authority
WO
WIPO (PCT)
Prior art keywords
coating
poly
molecules
prostaglandin
liquid
Prior art date
Application number
PCT/FR2012/052079
Other languages
French (fr)
Other versions
WO2013038119A3 (en
Inventor
Thierry Rimlinger
Pascal Dugand
Nolwenn Stephan
Original Assignee
Rexam Healthcare La Verpilliere
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexam Healthcare La Verpilliere filed Critical Rexam Healthcare La Verpilliere
Publication of WO2013038119A2 publication Critical patent/WO2013038119A2/en
Publication of WO2013038119A3 publication Critical patent/WO2013038119A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D183/00—Coating compositions based on macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon only; Coating compositions based on derivatives of such polymers
    • C09D183/04—Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D171/00—Coating compositions based on polyethers obtained by reactions forming an ether link in the main chain; Coating compositions based on derivatives of such polymers
    • C09D171/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D183/00—Coating compositions based on macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon only; Coating compositions based on derivatives of such polymers
    • C09D183/04—Polysiloxanes
    • C09D183/08—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
    • C09D5/14—Paints containing biocides, e.g. fungicides, insecticides or pesticides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/22—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen
    • C08G77/24—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen halogen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/80—Siloxanes having aromatic substituents, e.g. phenyl side groups
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D101/00—Coating compositions based on cellulose, modified cellulose, or cellulose derivatives
    • C09D101/08—Cellulose derivatives
    • C09D101/26—Cellulose ethers
    • C09D101/28—Alkyl ethers
    • C09D101/284—Alkyl ethers with hydroxylated hydrocarbon radicals

Definitions

  • the present invention relates to a device for storing and dispensing pharmaceutical liquid such as ophthalmic liquid.
  • the ophthalmic liquid comprises, as active principle, at least one prostaglandin or a prostaglandin analogue, especially for the treatment of glaucoma.
  • Prostaglandins or prostaglandin analogues are well known active ingredients, generally administered to humans or animals topically in the form of eye drops for the treatment of glaucoma. These active ingredients can also be used in combination with a second anti-glaucoma agent such as, for example, a beta-blocker, a carbonic anhydrase inhibitor or an alpha-adrenergic agonist.
  • a second anti-glaucoma agent such as, for example, a beta-blocker, a carbonic anhydrase inhibitor or an alpha-adrenergic agonist.
  • prostaglandins or prostaglandin analogues are not soluble in water, their dissolution in the preparation of eye drops presents some difficulties. Indeed, it is necessary to go through a preliminary step of solubilization of the active ingredient to obtain an aqueous solution ready to be distributed.
  • an anti-microbial preservative was often added.
  • these preservatives which could contribute to the solubilization of the active ingredient and its stabilization within the solution, are now deprecated because they can be toxic and pose problems of tolerance, especially in the context of a treatment of long-term such as the treatment of glaucoma. The solubilization of the active ingredient and its stability in the device is therefore likely to be affected.
  • the solution comprising the active ingredient must also be stable over time. Indeed, the liquid can be stored for up to thirty-six months in the device before its first opening, then about 1 month after its first opening, for example for administration at the rate of one drop in each eye per day.
  • a reduction in the concentration of active ingredient in the drops delivered is observed. This reduction in concentration may be due to absorption phenomena of the active ingredient in the parts of the device in contact with the solution and / or adsorption phenomena on these same parts. It may also be due to the absorption or adsorption of any other species present in the solution which could, by modifying the equilibrium of the solution, promote the adsorption or absorption of the active ingredient by parts of the solution. device in contact with the solution.
  • prostaglandins or prostaglandin analogues are generally introduced into the solution at low concentrations, such as a concentration of less than 1% by weight, or even less than 0.01% by weight.
  • One solution to this problem is to modify the formulation of the solution in order to make the solution stable and inert with respect to the material of the storage and dispensing device, even at low concentrations.
  • a device for dispensing product with or without a preservative for example, to comprise different polymer materials for the reservoir and for the various constituents of the dispensing nozzle, such as a valve support, a dispensing valve, air take-up member, filter element, filter element support, etc.
  • protein covers the following proteins or polypeptides: protein hormones, growth factors, cytokines, especially interleukins and interferons, chemokines, proteins of blood plasma, in particular albumin in the form of proteins. its different forms, coagulation factors or thrombosis, immunoglobulins, vaccine antigens from bacteria or viruses or parasites, extracellular matrix proteins, including collagen, elastin or others.
  • protein hormones protein hormones, growth factors, cytokines, especially interleukins and interferons, chemokines, proteins of blood plasma, in particular albumin in the form of proteins. its different forms, coagulation factors or thrombosis, immunoglobulins, vaccine antigens from bacteria or viruses or parasites, extracellular matrix proteins, including collagen, elastin or others.
  • cytokines especially interleukins and interferons
  • chemokines proteins of blood plasma
  • albumin in the form of proteins. its different forms, coagulation factors or thrombosis, immunoglobul
  • the object of the invention is to propose a device for storing and dispensing pharmaceutical liquids that makes it possible to guarantee the active ingredient content of the solution for a given time interval, without having to adapt the composition of the solution to the various materials of the device. .
  • the subject of the invention is a device for the storage and dispensing of pharmaceutical liquid comprising, on at least part of a surface internal device, a coating reducing the sorption of at least one of the species present in the liquid on the coated surface characterized in that the coating is hydrophobic.
  • the species present in the liquid is meant an active principle or any other species present in the solution which could, by modifying the equilibrium of the solution, promote the sorption of the active ingredient on the coated surface.
  • the species are chosen from a protein, a prostaglandin or a prostaglandin derivative.
  • sorption is meant the phenomena, combined or not, of absorption and adsorption of a molecule in or on a surface.
  • the elements of the device are generally made of thermoplastic polymer materials such as polyethylene (PE), polypropylene (PP), polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polyoxymethylene (POM), polyarylate (PAr), polyetherketone (PEK) fluorinated polymers (for example: polyvinylidene fluoride (PVDF), cycloolefinic polymers (COC) (for example the polymers sold under the trademark "TOPAS”), cycloolefinic copolymers (COP) (for example the copolymers sold under the trademark " Zeonex "), polytetrafluoroethylene (PTFE), polychlorotrifluoroethylene (PCTFE), polysulfone (PSU), ethylene-propylene-diene monomer (EPDM), or thermosetting type such as synthetic rubbers (for example: halobutyl rubber, nitrile rubber, polyisoprenes, and polychloroprene) or else
  • These devices may also comprise polysiloxane, such as, for example, polydimethylsiloxane (PDMS) and polydimethylvinylsiloxane.
  • PDMS polydimethylsiloxane
  • PVS polydimethylvinylsiloxane
  • the materials of the device are chosen from PE, PP, PET, PBT, COP and PDMS, alone or in mixtures.
  • the different elements of the device may be of different types of materials.
  • the reservoir may be PE, the PDMS air permeable member and the chlorobutyl rubber valve. It will be understood that these elements of the device may comprise one or more of the materials listed above, taken alone or in a mixture. "Mixed” also refers to the copolymers of these materials.
  • internal surface of the device each surface that can be in contact with the liquid to be dispensed before the latter is expelled out of the device through the liquid dispensing orifice carried by the dispensing nozzle.
  • coating reducing the sorption of the liquid on the coated surface a coating which significantly reduces the sorption of the active ingredient on the surface of the device carrying the coating that is to say a coating that reduces the sorption of minus 10% relative to an untreated surface, preferably at least 20%, more preferably at least 30%, more preferably at least 50%.
  • a device which makes it possible to guarantee the stability of the solution, in particular of an ophthalmic solution comprising prostaglandins, prostaglandin analogs or proteins, in that the active ingredient remains in solution. solution within a defined concentration range and for a given time interval.
  • the quantity of active ingredient delivered is indeed that required.
  • the coating is selected from the group consisting of fluorinated molecules.
  • the coating is chosen from groups consisting of fluorinated polymers of type or derivatives of polyethylene, phosphazene, silane and paraxylylene type molecules. More preferably, the coating is chosen from poly (bis (2,2,2-trifluoroethoxy) phosphazene) (PTFEP), perfluorodecyltrichlorosilane and poly (metafluoroparaxylylene).
  • the coating may be chosen from the group consisting of silicones and their derivatives, in particular in order to create a strong bond between the coating and the material of the coated surface to ensure that the coating adheres well. More particularly, the coating is chosen from fluorinated silicones such as fluorovinylmethyl silicones (FVMQ), phenylvinylmethyl silicones (PVMQ) or PDMS.
  • FVMQ fluorovinylmethyl silicones
  • PVMQ phenylvinylmethyl silicones
  • PDMS PDMS
  • the coating may be chosen from the group consisting of poly (paraxylylene) polymers, preferably from poly (chloroparaxylylene) polymers. More preferably, the coating may be chosen from poly (paraxylylene), poly (metachloroparaxylylene), poly (metadichloroparaxylylene) or poly (metafluoroparaxylylene).
  • the coating may be chosen from the group consisting of hydrophobically modified polyethylene glycol molecules or hydrophobically modified hydroxyethylcellulose molecules. More preferentially, the coating may be chosen from hydrophobically modified hydroxyethylcellulose marketed under the trademark "Natrosol Plus”.
  • the invention relates to a device for the storage and dispensing of pharmaceutical liquid comprising, on at least a part of an internal surface of the device, a coating reducing the sorption of at least one protein or a prostaglandin or a derivative of prostaglandin present in the liquid on the coated surface characterized in that the coating is hydrophobic.
  • the coating is chosen from silicones and their derivatives.
  • the device according to the invention is such that the coating is an organosilicone, especially chosen from polydimethylsiloxane, fluorovinylmethylsilicones or phenylvinylmethyl silicones.
  • the coating is selected from the group consisting of fluorinated molecules.
  • the coating of the device of the invention may be chosen from poly (bis (2,2,2-trifluoroethoxy) phosphazene), poly (metafluoroparaxylylene), polytetrafluoroethylene, perfluorodecyltrichlorosilane or fluorovinylmethylsilicones.
  • the coating is chosen from the group consisting of poly (paraxylylene) polymers, especially chosen from poly (paraxylylene), poly (metachloroparaxylylene), poly (metadichloroparaxylylene) or poly (metafluoroparaxylylene).
  • the coating is chosen from the group consisting of hydrophobically modified polyethylene glycol molecules or hydrophobically modified hydroxyethylcellulose molecules.
  • the invention also relates to the use of a coating described above, for reducing the sorption of at least one protein, at least one prostaglandin or at least one prostaglandin analogue to an internal surface of a device.
  • the coating may comprise or be constituted by a or more than one of all the molecules listed above for coating, alone or as a mixture. By “in a mixture”, the copolymers of these molecules are also targeted. It should also be noted that the molecules listed above for the coating may be mixed with polytetrafluoroethylene (PTFE).
  • PTFE polytetrafluoroethylene
  • the device may include the coating over the entire inner surface or a portion of the inner surface.
  • the coated portion of the inner surface depends on the nature of the material composing the various elements and / or the punctual or permanent nature of the contacting of said element with the liquid or the solution.
  • the portion of the inner surface coated by the coating is an air permeable member, a reservoir and / or any surface that may be in prolonged contact with the solution.
  • prolonged contact is meant contact greater than 6 months.
  • the invention also relates to a method of manufacturing a device according to the invention, wherein the coating is applied to at least a portion of the inner surface of the device.
  • the inner surface or the inner surface portion is pretreated by plasma treatment, by corona treatment; by flaming (treatment consisting in exposing the surface of a polymeric material to an oxidizing flame) or by treatment by the method known as "Pyrosil".
  • the invention finally relates to the use of a coating chosen from the group of fluorinated molecules, silicones and their derivatives, poly (paraxylylene) polymers, hydrophobically modified polyethylene glycol molecules or hydrophobically modified hydroxyethylcellulose molecules. to reduce the sorption as defined above.
  • the coating is used to reduce the sorption of at least one prostaglandin or at least one prostaglandin analogue.
  • the coating is used to reduce the sorption of at least one protein.
  • a coating of poly (bis (2,2,2-trifluoroethoxy) phosphazene) is deposited on the inner surface of a air permeable member to ensure that the air entering the device to replace the amount of liquid delivered is free of bacteria and / or particles.
  • the inner surface of the air permeable member is activated by plasma treatment with a power of 200 W with a flow rate of dinitrogen (N 2 ) of 10 sccm ("standard cubic centimeters per minute") for about 5 minutes .
  • a 1% solution of PTFEP in ethyl acetate is made. This solution is applied to the activated inner surface of the organ to form a continuous film.
  • the organ and the liquid film are then dried in an oven at 50 ° C for 24 hours to obtain an air permeable member whose inner surface comprises a PTFEP coating.
  • Example 2 Device Containing a Polv Coating (Paraxylylene)
  • a poly (paraxylylene) coating may also be deposited on the inner surface to be treated by gas phase polymerization.
  • a precursor such as [2,2] paracyclophane which is in a pulverulent solid form is used. This principle of deposition is broken down into three stages.
  • the solid paracyclophane is heated at a temperature above 100 ° C. to sublimate
  • the paracyclophane vapors pass into a pyrolysis zone where the temperature is higher than 500 ° C., which allows the rupture of the two aliphatic C-C bonds and the formation of two reactive paraxylylene molecules,
  • the paraxylylene molecules adsorb on the surfaces and polymerize spontaneously forming the poly (paraxylylene) film.
  • the thickness of the deposited film depends on the total coated surface as well as the amount of sublimed paracyclophane.
  • Example 3 Device comprising a fluorinated silicone coating (FVMQ).
  • FVMQ fluorinated silicone coating
  • the internal surface of the air-permeable member is activated by a plasma treatment with a power of 200 W with a flow rate of nitrogen (N 2 ) of 10 sccm ("Standard cubic centimeters per minute") for about 5 minutes.
  • N 2 flow rate of nitrogen
  • a 5% solution of FVMQ solution in ethyl acetate (for example a solution sold under the trademark Nusil MED10-6655 diluted 1/12 in ethyl acetate) is prepared. This solution is applied to the activated inner surface of the organ to form a continuous film.
  • the organ and the liquid film are then dried in an oven at 50 ° C for 24 hours to obtain an air permeable member whose surface comprises a FVMQ coating.
  • Example 4 Device comprising a phenyl silicone coating (PVMQ).
  • PVMQ phenyl silicone coating
  • the inner surface of the air permeable member is activated by plasma treatment with a power of 200 W with a flow rate of dinitrogen (N 2 ) of 10 sccm ("standard cubic centimeters per minute") for about 5 minutes .
  • N 2 dinitrogen
  • a 5% solution of PVMQ solution in hexane (for example a solution marketed under the trade name Nusil CV-1152 RTV) is produced. This solution is applied to the activated inner surface of the organ to form a continuous film.
  • the organ and the liquid film are then dried in an oven at 50 ° C for 24 hours to obtain an air permeable member whose surface comprises a PVMQ coating.
  • Example 5 Device Containing a Fluorosilane Coating: Perfluorodecyltrichlorosilane
  • the surface of the air permeable member is activated by a cold plasma treatment.
  • the cold plasma surface treatment is carried out in MVD type deposition equipment: the plasma is generated using an HF generator (200 Watt, 450 sccm) in a chamber whose diameter is compatible with plates Silicon diameter 200 mm. Under these conditions, the heating induced by the surface reactions remaining very low, the physical properties of the material are retained.
  • the plasma generated from 0 2 gaseous breaks the chemical bonds of the PDMS and form the hydroxyl groups that make the surface hydrophilic.
  • This treatment easy to implement and to introduce into a production line, not only induces a surface modification as such, but also intervenes as surface pre-modification before the covalent grafting of molecules chosen a priori to avoid the non-specific adsorption phenomenon.
  • a silicon oxide Si0 2 deposit is deposited (in a SiCI 4 atmosphere) to create a hooked layer in order to improve the silane grafting which will follow.
  • a covalent grafting of (1 H, 1 H, 2 H, 2 H) -perfluorodecyltrichlorosilane is carried out in the gas phase.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a device for storing and dispensing pharmaceutical liquid, such as ophthalmic liquid. More particularly, the ophthalmic liquid comprises, as active principle, at least one prostaglandin, at least one analogue of a prostaglandin or at least one protein, especially for the treatment of glaucoma. The device according to the invention comprises, on at least one part of an inner surface of the device, a coating that reduces the sorption of liquid on the coated surface, this coating being hydrophobic.

Description

Dispositif de stockage et de distribution de liquide  Liquid storage and dispensing device

La présente invention concerne un dispositif de stockage et de distribution de liquide pharmaceutique tel que du liquide ophtalmique. Plus particulièrement, le liquide ophtalmique comprend, en tant que principe actif, au moins une prostaglandine ou un analogue de prostaglandine, notamment pour le traitement du glaucome. The present invention relates to a device for storing and dispensing pharmaceutical liquid such as ophthalmic liquid. More particularly, the ophthalmic liquid comprises, as active principle, at least one prostaglandin or a prostaglandin analogue, especially for the treatment of glaucoma.

Les prostaglandines ou analogues de prostaglandines sont des principes actifs bien connus, généralement administrés à l'homme ou à l'animal par voie topique sous forme de collyre pour le traitement du glaucome. Ces principes actifs peuvent être également utilisés en association avec un deuxième agent anti-glaucomateux tel que par exemple, un béta-bloquant, un inhibiteur de l'anhydrase carbonique ou encore un agoniste alpha-adrénergique.  Prostaglandins or prostaglandin analogues are well known active ingredients, generally administered to humans or animals topically in the form of eye drops for the treatment of glaucoma. These active ingredients can also be used in combination with a second anti-glaucoma agent such as, for example, a beta-blocker, a carbonic anhydrase inhibitor or an alpha-adrenergic agonist.

La majorité des prostaglandines ou analogues de prostaglandine n'étant pas solubles dans l'eau, leur mise en solution lors de la préparation d'un collyre présente quelques difficultés. En effet, il est nécessaire de passer par une étape préalable de solubilisation du principe actif pour obtenir une solution aqueuse prête à être distribuée.  The majority of prostaglandins or prostaglandin analogues are not soluble in water, their dissolution in the preparation of eye drops presents some difficulties. Indeed, it is necessary to go through a preliminary step of solubilization of the active ingredient to obtain an aqueous solution ready to be distributed.

Par ailleurs, afin de garantir la stérilité de la solution après l'ouverture du dispositif, un agent conservateur anti-microbien était souvent ajouté. Or, ces agents conservateurs, qui pouvaient contribuer à la solubilisation du principe actif et sa stabilisation au sein de la solution, sont désormais déconseillés car ils peuvent s'avérer toxiques et poser des problèmes de tolérance, surtout dans le cadre d'un traitement de longue durée tel que le traitement d'un glaucome. La solubilisation du principe actif et sa stabilité dans le dispositif est donc susceptible de s'en trouver affectées.  Moreover, in order to guarantee the sterility of the solution after the opening of the device, an anti-microbial preservative was often added. However, these preservatives, which could contribute to the solubilization of the active ingredient and its stabilization within the solution, are now deprecated because they can be toxic and pose problems of tolerance, especially in the context of a treatment of long-term such as the treatment of glaucoma. The solubilization of the active ingredient and its stability in the device is therefore likely to be affected.

Enfin, la solution comprenant le principe actif doit être également stable dans le temps. En effet, le liquide peut être stocké jusqu'à trente-six mois dans le dispositif avant sa première ouverture, puis environ 1 mois après sa première ouverture, par exemple pour une administration au rythme d'une goutte dans chaque œil par jour. Or on constate, au cours du temps, une réduction de la concentration en principe actif dans les gouttes délivrées. Cette réduction de concentration peut être due à des phénomènes d'absorption du principe actif dans les parties du dispositif en contact avec la solution et/ou des phénomènes d'adsorption sur ces mêmes parties. Elle peut également être due à l'absorption ou l'adsorption de toute autre espèce présente dans la solution qui pourrait, par modification de l'équilibre de la solution, favoriser l'adsorption ou l'absorption du principe actif par des parties du dispositif en contact avec la solution. Ces phénomènes sont particulièrement critiques à faible concentration car ils ne permettent pas de garantir la délivrance de la quantité requise du principe actif au cours du temps. En effet, si le principe actif réagit, de façon réversible ou non, avec l'un des matériaux des composants du dispositif lorsqu'ils sont en contact, sa concentration dans la solution diminue et peut devenir trop faible pour avoir un effet thérapeutique optimal. Or, par exemple, les prostaglandines ou analogues de prostaglandines sont généralement introduites dans la solution à de faibles concentrations, telle qu'une concentration inférieure à 1 % en poids, voire inférieure à 0,01 % en poids. Finally, the solution comprising the active ingredient must also be stable over time. Indeed, the liquid can be stored for up to thirty-six months in the device before its first opening, then about 1 month after its first opening, for example for administration at the rate of one drop in each eye per day. However, over time, a reduction in the concentration of active ingredient in the drops delivered is observed. This reduction in concentration may be due to absorption phenomena of the active ingredient in the parts of the device in contact with the solution and / or adsorption phenomena on these same parts. It may also be due to the absorption or adsorption of any other species present in the solution which could, by modifying the equilibrium of the solution, promote the adsorption or absorption of the active ingredient by parts of the solution. device in contact with the solution. These phenomena are particularly critical at low concentrations because they do not ensure the delivery of the required amount of the active ingredient over time. Indeed, if the active ingredient reacts, reversibly or not, with one of the component materials of the device when in contact, its concentration in the solution decreases and may become too low to have an optimal therapeutic effect. However, for example, prostaglandins or prostaglandin analogues are generally introduced into the solution at low concentrations, such as a concentration of less than 1% by weight, or even less than 0.01% by weight.

Une solution à ce problème consiste à modifier la formulation de la solution afin de rendre la solution stable et inerte vis-à-vis du matériau du dispositif de stockage et de distribution et ce, même à faibles concentrations. Cependant, il est fréquent qu'un dispositif pour la distribution de produit avec ou sans conservateur puisse par exemple comprendre des matériaux polymères différents pour le réservoir et pour les différents constituants de l'embout de distribution, tels qu'un support de valve, une valve de distribution, un organe de reprise d'air, un élément filtrant, un support d'élément filtrant, etc.  One solution to this problem is to modify the formulation of the solution in order to make the solution stable and inert with respect to the material of the storage and dispensing device, even at low concentrations. However, it is common for a device for dispensing product with or without a preservative, for example, to comprise different polymer materials for the reservoir and for the various constituents of the dispensing nozzle, such as a valve support, a dispensing valve, air take-up member, filter element, filter element support, etc.

Il est donc difficile d'adapter la formulation de la solution à tous les matériaux polymères du dispositif en contact avec la solution.  It is therefore difficult to adapt the formulation of the solution to all the polymeric materials of the device in contact with the solution.

Des problèmes analogues de sorption des protéines se posent également lorsque l'on utilise des protéines en tant que principe actif en faibles concentrations pour d'autres utilisations thérapeutiques ou non.  Similar problems of protein sorption also arise when using proteins as an active ingredient in low concentrations for other therapeutic uses or not.

Dans l'invention, le terme « protéine » couvre les protéines ou polypeptides suivants : les hormones protéiques, les facteurs de croissances, les cytokines, notamment les interleukines et les interférons, les chimiokines, les protéines du plasma sanguin, notamment l'albumine sous ses différentes formes, les facteurs de coagulation ou de thrombose, les immunoglobulines, les antigènes vaccinaux issus de bactéries ou de virus ou de parasites, des protéines de la matrice extracellulaire, notamment le collagène, l'élastine ou autres. La précédente liste n'a pas de caractère limitatif, et l'homme de métier du domaine de l'invention est capable de déterminer les protéines d'intérêt.  In the invention, the term "protein" covers the following proteins or polypeptides: protein hormones, growth factors, cytokines, especially interleukins and interferons, chemokines, proteins of blood plasma, in particular albumin in the form of proteins. its different forms, coagulation factors or thrombosis, immunoglobulins, vaccine antigens from bacteria or viruses or parasites, extracellular matrix proteins, including collagen, elastin or others. The previous list is not limiting in nature, and one skilled in the field of the invention is capable of determining the proteins of interest.

L'invention a pour but de proposer un dispositif de stockage et de distribution de liquide pharmaceutique permettant de garantir la teneur en principe actif de la solution pendant un intervalle donné de temps, sans avoir à adapter la composition de la solution aux différents matériaux du dispositif.  The object of the invention is to propose a device for storing and dispensing pharmaceutical liquids that makes it possible to guarantee the active ingredient content of the solution for a given time interval, without having to adapt the composition of the solution to the various materials of the device. .

A cet effet, l'invention a pour objet un dispositif pour le stockage et la distribution de liquide pharmaceutique comprenant, sur au moins une partie d'une surface interne du dispositif, un revêtement réduisant la sorption d'au moins l'une des espèces présentes dans le liquide sur la surface revêtue caractérisé en ce que le revêtement est hydrophobe. For this purpose, the subject of the invention is a device for the storage and dispensing of pharmaceutical liquid comprising, on at least part of a surface internal device, a coating reducing the sorption of at least one of the species present in the liquid on the coated surface characterized in that the coating is hydrophobic.

Par « au moins une des espèces présentes dans le liquide », on entend un principe actif ou toute autre espèce présente dans la solution qui pourrait, par modification de l'équilibre de la solution, favoriser la sorption du principe actif sur la surface revêtue. Avantageusement, les espèces sont choisies parmi une protéine, une prostaglandine ou un dérivé de prostaglandine.  By "at least one of the species present in the liquid" is meant an active principle or any other species present in the solution which could, by modifying the equilibrium of the solution, promote the sorption of the active ingredient on the coated surface. Advantageously, the species are chosen from a protein, a prostaglandin or a prostaglandin derivative.

Par « sorption », on désigne les phénomènes, combinés ou non, d'absorption et d'adsorption d'une molécule dans ou sur une surface.  By "sorption" is meant the phenomena, combined or not, of absorption and adsorption of a molecule in or on a surface.

On entend par « dispositif de stockage et de distribution », un dispositif comprenant un réservoir de stockage du liquide à distribuer et un embout de distribution du produit. Ces dispositifs peuvent par exemple être destinés à la distribution de gouttes et comporter une valve de distribution de liquide et/ou un organe perméable à l'air. Ces dispositifs peuvent également être destinés à l'injection de liquide, par exemple sous forme d'une seringue munie d'une aiguille d'injection.  The term "storage and distribution device", a device comprising a storage tank of the liquid to be dispensed and a product dispensing tip. These devices may for example be intended for dispensing drops and comprise a liquid distribution valve and / or an air permeable member. These devices may also be intended for the injection of liquid, for example in the form of a syringe provided with an injection needle.

Les éléments du dispositif sont généralement en matériaux polymères du type thermoplastique comme polyéthylène (PE), polypropylène (PP), polyéthylène- téréphtalate (PET), polybutylène théréphtalate (PBT), polyoxyméthylène (POM), polyarylate (PAr), polyéthercétone (PEK), polymères fluorés (par exemple : polyfluorure de vinylidène (PVDF), polymères cyclo-oléfiniques (COC) (par exemple les polymères commercialisés sous la marque « TOPAS »), copolymères cyclooléfiniques (COP) (par exemple les copolymères commercialisés sous la marque « Zeonex »), polytétrafluoroéthylène (PTFE), polychlorotrifluoroéthylène (PCTFE)), polysulfone (PSU), éthylène-propylène-diène monomère (EPDM), ou de type thermodurcissable comme les caoutchoucs synthétiques (par exemple: les caoutchouc halogénobutyles, les caoutchoucs nitriles, les polyisoprènes, et les polychloroprène) ou encore du type élastomères thermoplastiques (par exemple : copolymère EPDM-PP commercialisé sous la marque « Santoprène », copolymère bloc styrène-éthylène-butylène-styrène (SEBS), etc.), seuls ou en mélanges. Ces dispositifs peuvent également comprendre du polysiloxane, comme par exemple du polydiméthylsiloxane (PDMS) et du polydimethylvinylsiloxane.  The elements of the device are generally made of thermoplastic polymer materials such as polyethylene (PE), polypropylene (PP), polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polyoxymethylene (POM), polyarylate (PAr), polyetherketone (PEK) fluorinated polymers (for example: polyvinylidene fluoride (PVDF), cycloolefinic polymers (COC) (for example the polymers sold under the trademark "TOPAS"), cycloolefinic copolymers (COP) (for example the copolymers sold under the trademark " Zeonex "), polytetrafluoroethylene (PTFE), polychlorotrifluoroethylene (PCTFE), polysulfone (PSU), ethylene-propylene-diene monomer (EPDM), or thermosetting type such as synthetic rubbers (for example: halobutyl rubber, nitrile rubber, polyisoprenes, and polychloroprene) or else of the thermoplastic elastomer type (for example: commercial EPDM-PP copolymer). under the trademark "Santoprene", styrene-ethylene-butylene-styrene block copolymer (SEBS), etc.), alone or in mixtures. These devices may also comprise polysiloxane, such as, for example, polydimethylsiloxane (PDMS) and polydimethylvinylsiloxane.

Préférentiellement, les matériaux du dispositif sont choisis parmi le PE, le PP, le PET, le PBT, le COP et le PDMS, seuls ou en mélanges. Les différents éléments du dispositif peuvent être en matériaux de types différents. Ainsi, le réservoir peut être en PE, l'organe perméable à l'air en PDMS et la valve en caoutchouc chlorobutyle. On comprendra que ces éléments du dispositif peuvent comprendre l'un ou plusieurs des matériaux listés ci-dessus, pris seuls ou en mélange. Par « en mélange », on vise également les copolymères de ces matériaux. Preferably, the materials of the device are chosen from PE, PP, PET, PBT, COP and PDMS, alone or in mixtures. The different elements of the device may be of different types of materials. Thus, the reservoir may be PE, the PDMS air permeable member and the chlorobutyl rubber valve. It will be understood that these elements of the device may comprise one or more of the materials listed above, taken alone or in a mixture. "Mixed" also refers to the copolymers of these materials.

On entend par « surface interne » du dispositif chaque surface qui peut être en contact avec le liquide à distribuer avant que ce dernier ne soit expulsé hors du dispositif par l'orifice de distribution du liquide porté par l'embout de distribution. The term "internal surface" of the device each surface that can be in contact with the liquid to be dispensed before the latter is expelled out of the device through the liquid dispensing orifice carried by the dispensing nozzle.

On entend par « revêtement réduisant la sorption du liquide sur la surface revêtue », un revêtement qui réduit notablement la sorption du principe actif sur la surface du dispositif portant le revêtement c'est-à-dire un revêtement qui réduit la sorption d'au moins 10% par rapport à une surface non traitée, de préférence d'au moins 20%, plus préférentiellement d'au moins 30%, plus préférentiellement encore d'au moins 50%. The term "coating reducing the sorption of the liquid on the coated surface", a coating which significantly reduces the sorption of the active ingredient on the surface of the device carrying the coating that is to say a coating that reduces the sorption of minus 10% relative to an untreated surface, preferably at least 20%, more preferably at least 30%, more preferably at least 50%.

Ainsi, grâce à l'invention, on obtient un dispositif qui permet de garantir la stabilité de la solution, en particulier d'une solution ophtalmique comportant des prostaglandines, des analogues de prostaglandine ou des protéines, en ce sens que le principe actif reste en solution dans une gamme de concentration définie et pendant un intervalle de temps donné. Ainsi, à chaque délivrance d'une goutte de produit, la quantité de principe actif délivré est bien celle requise.  Thus, thanks to the invention, a device is obtained which makes it possible to guarantee the stability of the solution, in particular of an ophthalmic solution comprising prostaglandins, prostaglandin analogs or proteins, in that the active ingredient remains in solution. solution within a defined concentration range and for a given time interval. Thus, with each delivery of a drop of product, the quantity of active ingredient delivered is indeed that required.

En outre, comme la sorption est très limitée, voire nulle, il n'est plus nécessaire de stocker le dispositif dans un réfrigérateur avant ou pendant utilisation.  In addition, since the sorption is very limited, or even zero, it is no longer necessary to store the device in a refrigerator before or during use.

Selon un premier mode de réalisation, le revêtement est choisi parmi le groupe constitué par les molécules fluorées. De préférence, le revêtement est choisi parmi les groupes constitués par les polymères fluorés de type ou dérivés de molécules de type polyéthylène, phosphazène, silane et paraxylylène. De manière plus préférentielle, le revêtement est choisi parmi le poly(bis(2,2,2- trifluoroéthoxy)phosphazène) (PTFEP), le perfluorodecyltrichlorosilane, le poly(métafluoroparaxylylène).  According to a first embodiment, the coating is selected from the group consisting of fluorinated molecules. Preferably, the coating is chosen from groups consisting of fluorinated polymers of type or derivatives of polyethylene, phosphazene, silane and paraxylylene type molecules. More preferably, the coating is chosen from poly (bis (2,2,2-trifluoroethoxy) phosphazene) (PTFEP), perfluorodecyltrichlorosilane and poly (metafluoroparaxylylene).

Selon un second mode de réalisation, le revêtement peut être choisi parmi le groupe constitué par les silicones et leurs dérivés afin notamment de créer une liaison forte entre le revêtement et le matériau de la surface revêtue pour garantir le bon accrochage du revêtement. Plus particulièrement, le revêtement est choisi parmi les silicones fluorés tels que les fluorovinylméthyl silicones (FVMQ), les phénylvinylméthyl silicones (PVMQ) ou le PDMS.  According to a second embodiment, the coating may be chosen from the group consisting of silicones and their derivatives, in particular in order to create a strong bond between the coating and the material of the coated surface to ensure that the coating adheres well. More particularly, the coating is chosen from fluorinated silicones such as fluorovinylmethyl silicones (FVMQ), phenylvinylmethyl silicones (PVMQ) or PDMS.

Selon un troisième mode de réalisation, le revêtement peut être choisi parmi le groupe constitué par les polymères de poly(paraxylylène), de préférence, parmi les polymères de poly(chloroparaxylylène). De manière plus préférentielle, le revêtement peut être choisi parmi le poly(paraxylylène), le poly(métachloroparaxylylène), le poly(métadichloroparaxylylène) ou le poly(métafluoroparaxylylène). According to a third embodiment, the coating may be chosen from the group consisting of poly (paraxylylene) polymers, preferably from poly (chloroparaxylylene) polymers. More preferably, the coating may be chosen from poly (paraxylylene), poly (metachloroparaxylylene), poly (metadichloroparaxylylene) or poly (metafluoroparaxylylene).

Selon un quatrième mode de réalisation, le revêtement peut être choisi parmi le groupe constitué par les molécules de polyéthylène glycol modifiées hydrophobiquement ou les molécules d'hydroxyéthylcellulose modifiée hydrophobiquement. Plus préférentiellement, le revêtement peut être choisi parmi l'hydroxyéthylcellulose modifiée hydrophobiquement commercialisée sous la marque « Natrosol Plus ».  According to a fourth embodiment, the coating may be chosen from the group consisting of hydrophobically modified polyethylene glycol molecules or hydrophobically modified hydroxyethylcellulose molecules. More preferentially, the coating may be chosen from hydrophobically modified hydroxyethylcellulose marketed under the trademark "Natrosol Plus".

Avantageusement, l'invention concerne un dispositif pour le stockage et la distribution de liquide pharmaceutique comprenant, sur au moins une partie d'une surface interne du dispositif, un revêtement réduisant la sorption d'au-moins une protéine ou une prostaglandine ou un dérivé de prostaglandine présents dans le liquide sur la surface revêtue caractérisé en ce que le revêtement est hydrophobe.  Advantageously, the invention relates to a device for the storage and dispensing of pharmaceutical liquid comprising, on at least a part of an internal surface of the device, a coating reducing the sorption of at least one protein or a prostaglandin or a derivative of prostaglandin present in the liquid on the coated surface characterized in that the coating is hydrophobic.

Dans un mode réalisation avantageux, le revêtement est choisi parmi les silicones et leurs dérivés.  In an advantageous embodiment, the coating is chosen from silicones and their derivatives.

Le dispositif selon l'invention est tel que le revêtement est un organosiliconé, notamment choisi parmi le polydiméthylsiloxane, les fluorovinylméthylsilicones ou les phénylvinylméthyl silicones.  The device according to the invention is such that the coating is an organosilicone, especially chosen from polydimethylsiloxane, fluorovinylmethylsilicones or phenylvinylmethyl silicones.

Dans un autre mode de réalisation encore plus avantageux, le revêtement est choisi parmi le groupe constitué par les molécules fluorées.  In another even more advantageous embodiment, the coating is selected from the group consisting of fluorinated molecules.

Le revêtement du dispositif de l'invention peut être choisi parmi le poly(bis(2,2,2- trifluoroéthoxy)phosphazène), le poly(métafluoroparaxylylène), le polytétrafluoroéthylène, le perfluorodecyltrichlorosilane ou les fluorovinylméthylsilicones.  The coating of the device of the invention may be chosen from poly (bis (2,2,2-trifluoroethoxy) phosphazene), poly (metafluoroparaxylylene), polytetrafluoroethylene, perfluorodecyltrichlorosilane or fluorovinylmethylsilicones.

Selon un autre aspect avantageux, le revêtement est choisi parmi le groupe constitué par les polymères de poly(paraxylylène), notamment choisi parmi le poly(paraxylylène), le poly(métachloroparaxylylène), le poly(métadichloroparaxylylène) ou le poly(métafluoroparaxylylène).  According to another advantageous aspect, the coating is chosen from the group consisting of poly (paraxylylene) polymers, especially chosen from poly (paraxylylene), poly (metachloroparaxylylene), poly (metadichloroparaxylylene) or poly (metafluoroparaxylylene).

Selon encore un autre aspect avantageux, le revêtement est choisi parmi le groupe constitué par les molécules de polyéthylène glycol modifiées hydrophobiquement ou les molécules d'hydroxyéthylcellulose modifiées hydrophobiquement.  According to yet another advantageous aspect, the coating is chosen from the group consisting of hydrophobically modified polyethylene glycol molecules or hydrophobically modified hydroxyethylcellulose molecules.

L'invention concerne également l'utilisation d'un revêtement décrit précédemment, pour réduire la sorption d'au moins une protéine, d'au moins une prostaglandine ou d'au moins un analogue d'une prostaglandine sur une surface interne d'un dispositif.  The invention also relates to the use of a coating described above, for reducing the sorption of at least one protein, at least one prostaglandin or at least one prostaglandin analogue to an internal surface of a device.

On comprendra que le revêtement peut comprendre ou être constitué par une ou plusieurs de l'ensemble de toutes les molécules listées ci-dessus pour le revêtement, prises seules ou en mélange. Par « en mélange », on vise également les copolymères de ces molécules. On notera par ailleurs que les molécules listées ci-dessus pour le revêtement peuvent être en mélange avec du polytétrafluoroéthylène (PTFE). It will be understood that the coating may comprise or be constituted by a or more than one of all the molecules listed above for coating, alone or as a mixture. By "in a mixture", the copolymers of these molecules are also targeted. It should also be noted that the molecules listed above for the coating may be mixed with polytetrafluoroethylene (PTFE).

Le dispositif peut comporter le revêtement sur l'intégralité de la surface interne ou sur une partie de la surface interne. La partie revêtue de la surface interne dépend de la nature du matériau composant les différents éléments et/ou du caractère ponctuel ou permanent de la mise en contact dudit élément avec le liquide ou la solution. Avantageusement, la partie de la surface interne revêtue par le revêtement est un organe perméable à l'air, un réservoir et/ou toute surface pouvant être en contact prolongé avec la solution. Par « contact prolongé », on entend un contact supérieur à 6 mois.  The device may include the coating over the entire inner surface or a portion of the inner surface. The coated portion of the inner surface depends on the nature of the material composing the various elements and / or the punctual or permanent nature of the contacting of said element with the liquid or the solution. Advantageously, the portion of the inner surface coated by the coating is an air permeable member, a reservoir and / or any surface that may be in prolonged contact with the solution. By "prolonged contact" is meant contact greater than 6 months.

L'invention concerne également un procédé de fabrication d'un dispositif selon l'invention, dans lequel le revêtement est appliqué sur au moins une partie de la surface interne du dispositif.  The invention also relates to a method of manufacturing a device according to the invention, wherein the coating is applied to at least a portion of the inner surface of the device.

Avantageusement, avant de déposer le revêtement, la surface interne ou la partie de surface interne est pré-traitée par traitement plasma, par traitement corona ; par un flammage (traitement consistant à exposer la surface d'un matériau polymère à une flamme oxydante) ou encore par un traitement par la méthode connue sous le nom de « Pyrosil ».  Advantageously, before depositing the coating, the inner surface or the inner surface portion is pretreated by plasma treatment, by corona treatment; by flaming (treatment consisting in exposing the surface of a polymeric material to an oxidizing flame) or by treatment by the method known as "Pyrosil".

L'invention concerne enfin l'utilisation d'un revêtement choisi parmi le groupe des molécules fluorées, des silicones et de leurs dérivés, des polymères de poly(paraxylylène), des molécules de polyéthylène glycol modifiées hydrophobiquement ou des molécules d'hydroxyéthylcellulose modifiées hydrophobiquement, pour réduire la sorption telle que définie précédemment.  The invention finally relates to the use of a coating chosen from the group of fluorinated molecules, silicones and their derivatives, poly (paraxylylene) polymers, hydrophobically modified polyethylene glycol molecules or hydrophobically modified hydroxyethylcellulose molecules. to reduce the sorption as defined above.

On comprend que cette utilisation pour réduire la sorption de la prostaglandine, de l'analogue de la prostaglandine ou de la protéine peut être envisagée avec un revêtement comprenant ou constitué de l'une quelconque des molécules listées ci- dessus pour le revêtement, prise seule ou en mélange les unes avec les autres.  It is understood that this use for reducing the sorption of prostaglandin, prostaglandin analogue or protein may be contemplated with a coating comprising or consisting of any of the molecules listed above for coating, taken alone. or mixed with each other.

Dans un mode de réalisation, on utilise le revêtement pour réduire la sorption d'au moins une prostaglandine ou d'au moins un analogue d'une prostaglandine.  In one embodiment, the coating is used to reduce the sorption of at least one prostaglandin or at least one prostaglandin analogue.

Dans un autre mode de réalisation, on utilise le revêtement pour réduire la sorption d'au moins une protéine.  In another embodiment, the coating is used to reduce the sorption of at least one protein.

Exemple 1 : Dispositif comportant un revêtement en PTFEP  Example 1 Device Comprising a PTFEP Coating

Dans cet exemple, un revêtement de poly(bis(2,2,2- trifluoroéthoxy)phosphazène) (PTFEP) est déposé sur la surface interne d'un organe perméable à l'air permettant de s'assurer que l'air entrant dans le dispositif pour remplacer la quantité de liquide délivré est exempt de bactéries et/ou de particules. In this example, a coating of poly (bis (2,2,2-trifluoroethoxy) phosphazene) (PTFEP) is deposited on the inner surface of a air permeable member to ensure that the air entering the device to replace the amount of liquid delivered is free of bacteria and / or particles.

On rappelle que l'on entend par « surface interne » du dispositif, chaque surface qui peut être en contact avec le liquide à distribuer avant que ce dernier ne soit expulsé hors du dispositif par l'orifice de distribution du liquide porté par l'embout de distribution.  It is recalled that the term "internal surface" of the device, each surface that can be in contact with the liquid to be dispensed before the latter is expelled from the device through the liquid dispensing orifice carried by the nozzle of distribution.

La surface interne de l'organe perméable à l'air est activée par un traitement plasma d'une puissance de 200 W avec un débit de diazote (N2) de 10 sccm (« standard cubic centimeters per minute ») pendant environ 5 minutes. The inner surface of the air permeable member is activated by plasma treatment with a power of 200 W with a flow rate of dinitrogen (N 2 ) of 10 sccm ("standard cubic centimeters per minute") for about 5 minutes .

On réalise une solution à 1 % de PTFEP dans de l'acétate d'éthyle. Cette solution est appliquée sur la surface interne activée de l'organe afin de former un film continu.  A 1% solution of PTFEP in ethyl acetate is made. This solution is applied to the activated inner surface of the organ to form a continuous film.

L'organe et le film liquide sont ensuite mis à sécher dans une étuve à 50°C pendant 24h pour obtenir un organe perméable à l'air dont la surface interne comprend un revêtement de PTFEP.  The organ and the liquid film are then dried in an oven at 50 ° C for 24 hours to obtain an air permeable member whose inner surface comprises a PTFEP coating.

Exemple 2 : Dispositif comportant un revêtement en polv( paraxylylène)  Example 2 Device Containing a Polv Coating (Paraxylylene)

Un revêtement de poly(paraxylylène) peut également être déposé sur la surface interne à traiter par polymérisation en phase gazeuse.  A poly (paraxylylene) coating may also be deposited on the inner surface to be treated by gas phase polymerization.

On utilise par exemple un précurseur tel que du [2,2]paracyclophane qui se présente sous une forme solide pulvérulente. Ce principe de déposition se décompose en trois étapes.  For example, a precursor such as [2,2] paracyclophane which is in a pulverulent solid form is used. This principle of deposition is broken down into three stages.

Sous vide primaire (~10~1 Pa) : Under primary vacuum (~ 10 ~ 1 Pa):

- le paracyclophane solide est chauffé à une température supérieure à 100°C pour se sublimer,  the solid paracyclophane is heated at a temperature above 100 ° C. to sublimate,

- les vapeurs de paracyclophane passent dans une zone de pyrolyse où la température est supérieure à 500°C ce qui permet la rupture des deux liaisons C- C aliphatiques et la formation de deux molécules de paraxylylène réactives,  the paracyclophane vapors pass into a pyrolysis zone where the temperature is higher than 500 ° C., which allows the rupture of the two aliphatic C-C bonds and the formation of two reactive paraxylylene molecules,

- enfin, en pénétrant dans la chambre de déposition à température ambiante, les molécules de paraxylylène s'adsorbent sur les surfaces et polymérisent spontanément formant le film de poly(paraxylylène).  Finally, by penetrating into the deposition chamber at room temperature, the paraxylylene molecules adsorb on the surfaces and polymerize spontaneously forming the poly (paraxylylene) film.

L'épaisseur du film déposé dépend de la surface totale revêtue ainsi que de la quantité de paracyclophane sublimée.  The thickness of the deposited film depends on the total coated surface as well as the amount of sublimed paracyclophane.

Exemple 3 : Dispositif comportant un revêtement en silicone fluoré (FVMQ). La surface interne de l'organe perméable à l'air est activée par un traitement plasma d'une puissance de 200 W avec un débit de diazote (N2) de 10 sccm (« standard cubic centimeters per minute ») pendant environ 5 minutes. Example 3: Device comprising a fluorinated silicone coating (FVMQ). The internal surface of the air-permeable member is activated by a plasma treatment with a power of 200 W with a flow rate of nitrogen (N 2 ) of 10 sccm ("Standard cubic centimeters per minute") for about 5 minutes.

On réalise une solution à 5% de solution de FVMQ dans de l'acétate d'éthyle (par exemple une solution commercialisée sous la marque Nusil MED10-6655 diluée au 1/12 dans l'acétate d'éthyle). Cette solution est appliquée sur la surface interne activée de l'organe afin de former un film continu.  A 5% solution of FVMQ solution in ethyl acetate (for example a solution sold under the trademark Nusil MED10-6655 diluted 1/12 in ethyl acetate) is prepared. This solution is applied to the activated inner surface of the organ to form a continuous film.

L'organe et le film liquide sont ensuite mis à sécher dans une étuve à 50°C pendant 24h pour obtenir un organe perméable à l'air dont la surface comprend un revêtement de FVMQ.  The organ and the liquid film are then dried in an oven at 50 ° C for 24 hours to obtain an air permeable member whose surface comprises a FVMQ coating.

Exemple 4 : Dispositif comportant un revêtement en silicone phénylé (PVMQ). La surface interne de l'organe perméable à l'air est activée par un traitement plasma d'une puissance de 200 W avec un débit de diazote (N2) de 10 sccm (« standard cubic centimeters per minute ») pendant environ 5 minutes. Example 4: Device comprising a phenyl silicone coating (PVMQ). The inner surface of the air permeable member is activated by plasma treatment with a power of 200 W with a flow rate of dinitrogen (N 2 ) of 10 sccm ("standard cubic centimeters per minute") for about 5 minutes .

On réalise une solution à 5% de solution de PVMQ dans l'hexane (par exemple une solution commercialisée sous la marque Nusil CV-1152 RTV). Cette solution est appliquée sur la surface interne activée de l'organe afin de former un film continu.  A 5% solution of PVMQ solution in hexane (for example a solution marketed under the trade name Nusil CV-1152 RTV) is produced. This solution is applied to the activated inner surface of the organ to form a continuous film.

L'organe et le film liquide sont ensuite mis à sécher dans une étuve à 50°C pendant 24h pour obtenir un organe perméable à l'air dont la surface comprend un revêtement de PVMQ.  The organ and the liquid film are then dried in an oven at 50 ° C for 24 hours to obtain an air permeable member whose surface comprises a PVMQ coating.

Exemple 5 : Dispositif comportant un revêtement en fluorosilane : le perfluorodecyltrichlorosilane  Example 5 Device Containing a Fluorosilane Coating: Perfluorodecyltrichlorosilane

La surface de l'organe perméable à l'air est activée par un traitement plasma froid. Le traitement de surface par plasma froid est réalisé dans un équipement de dépôt type MVD : la génération du plasma se fait à l'aide d'un générateur HF (200 Watt, 450 sccm) dans une chambre dont le diamètre est compatible avec des plaques de silicium de diamètre 200 mm. Dans ces conditions, réchauffement induit par les réactions en surface restant très faible, les propriétés physiques du matériau sont conservées. Le plasma, généré à partir d'02 gazeux permet de rompre les liaisons chimiques du PDMS et de former les groupements hydroxyles qui rendent la surface hydrophile. Ce traitement, facile à mettre en oeuvre et à introduire dans une chaîne de production, induit non seulement une modification de surface en tant que telle, mais intervient aussi comme pré-modification de surface avant le greffage covalent de molécules choisies a priori pour éviter le phénomène d'adsorption non spécifique. The surface of the air permeable member is activated by a cold plasma treatment. The cold plasma surface treatment is carried out in MVD type deposition equipment: the plasma is generated using an HF generator (200 Watt, 450 sccm) in a chamber whose diameter is compatible with plates Silicon diameter 200 mm. Under these conditions, the heating induced by the surface reactions remaining very low, the physical properties of the material are retained. The plasma, generated from 0 2 gaseous breaks the chemical bonds of the PDMS and form the hydroxyl groups that make the surface hydrophilic. This treatment, easy to implement and to introduce into a production line, not only induces a surface modification as such, but also intervenes as surface pre-modification before the covalent grafting of molecules chosen a priori to avoid the non-specific adsorption phenomenon.

On réalise ensuite un dépôt d'oxyde de silicium Si02 (sous atmosphère de SiCI4) pour créer une couche d'accroché afin d'améliorer le greffage de silane qui va suivre. Enfin on réalise un greffage covalent, en phase gazeuse, du (1 H, 1 H, 2H, 2H)- perfluorodecyltrichlorosilane. Subsequently, a silicon oxide Si0 2 deposit is deposited (in a SiCI 4 atmosphere) to create a hooked layer in order to improve the silane grafting which will follow. Finally, a covalent grafting of (1 H, 1 H, 2 H, 2 H) -perfluorodecyltrichlorosilane is carried out in the gas phase.

Claims

REVENDICATIONS 1 . Dispositif pour le stockage et la distribution de liquide pharmaceutique comprenant, sur au moins une partie d'une surface interne du dispositif, un revêtement réduisant la sorption d'au-moins une protéine ou une prostaglandine ou un dérivé de prostaglandine présents dans le liquide sur la surface revêtue caractérisé en ce que le revêtement est hydrophobe. 1. Device for the storage and dispensing of pharmaceutical liquid comprising, on at least a part of an internal surface of the device, a coating reducing the sorption of at least one protein or a prostaglandin or a prostaglandin derivative present in the liquid on the coated surface characterized in that the coating is hydrophobic. 2. Dispositif selon la revendication 1 , dans lequel le revêtement est choisi parmi les silicones et leurs dérivés.  2. Device according to claim 1, wherein the coating is selected from silicones and their derivatives. 3. Dispositif selon la revendication précédente, dans lequel le revêtement est un organosiliconé, notamment choisi parmi le polydiméthylsiloxane, les fluorovinylméthylsilicones ou les phénylvinylméthyl silicones.  3. Device according to the preceding claim, wherein the coating is an organosilicone, especially selected from polydimethylsiloxane, fluorovinylmethylsilicones or phenylvinylmethyl silicones. 4. Dispositif selon l'une quelconque des revendications 1 à 3, dans lequel le revêtement est choisi parmi le groupe constitué par les molécules fluorées.  4. Device according to any one of claims 1 to 3, wherein the coating is selected from the group consisting of fluorinated molecules. 5. Dispositif selon la revendication précédente, dans lequel le revêtement est choisi parmi le poly(bis(2,2,2-trifluoroéthoxy)phosphazène), le poly(métafluoroparaxylylène), le polytétrafluoroéthylène, le perfluorodecyltrichlorosilane ou les fluorovinylméthylsilicones.  5. Device according to the preceding claim, wherein the coating is selected from poly (bis (2,2,2-trifluoroethoxy) phosphazene), poly (metafluoroparaxylylene), polytetrafluoroethylene, perfluorodecyltrichlorosilane or fluorovinylmethylsilicones. 6. Dispositif selon la revendication 1 , dans lequel le revêtement est choisi parmi le groupe constitué par les polymères de poly(paraxylylène).  The device of claim 1, wherein the coating is selected from the group consisting of poly (paraxylylene) polymers. 7. Dispositif selon la revendication précédente, dans lequel le revêtement est choisi parmi le poly(paraxylylène), le poly(métachloroparaxylylène), le poly(métadichloroparaxylylène) ou le poly(métafluoroparaxylylène).  7. Device according to the preceding claim, wherein the coating is selected from poly (paraxylylene), poly (metachloroparaxylylene), poly (metadichloroparaxylylene) or poly (metafluoroparaxylylene). 8. Dispositif selon la revendication 1 , dans lequel le revêtement est choisi parmi le groupe constitué par les molécules de polyéthylène glycol modifiées hydrophobiquement ou les molécules d'hydroxyéthylcellulose modifiées hydrophobiquement.  The device of claim 1, wherein the coating is selected from the group consisting of hydrophobically modified polyethylene glycol molecules or hydrophobically modified hydroxyethylcellulose molecules. 9. Dispositif selon l'une quelconque des revendications précédentes, dans lequel la partie de la surface interne revêtue par le revêtement est un organe perméable à l'air ou un réservoir.  9. Device according to any one of the preceding claims, wherein the portion of the inner surface coated by the coating is an air permeable member or a reservoir. 10. Procédé de fabrication d'un dispositif selon l'une quelconque des revendications 1 à 9, dans lequel le revêtement est appliqué sur au moins une partie de la surface interne du dispositif.  10. A method of manufacturing a device according to any one of claims 1 to 9, wherein the coating is applied on at least a portion of the inner surface of the device. 1 1 . Procédé selon la revendication précédente, dans lequel, avant de déposer le revêtement, la partie de la surface interne est pré-traitée par traitement plasma ou par traitement Corona.  1 1. Method according to the preceding claim, wherein, before depositing the coating, the portion of the inner surface is pretreated by plasma treatment or corona treatment. 12. Utilisation d'un revêtement choisi parmi le groupe des silicones et de leurs dérivés, des molécules fluorées, des polymères de poly(paraxylylène), des molécules de polyéthylène glycol modifiées hydrophobiquement ou des molécules d'hydroxyéthylcellulose modifiées hydrophobiquement, pour réduire la sorption d'au moins une protéine, d'au moins une prostaglandine ou d'au moins un analogue d'une prostaglandine sur une surface interne d'un dispositif. 12. Use of a coating selected from the group of silicones and their derivatives, fluorinated molecules, poly (paraxylylene) polymers, hydrophobically modified polyethylene glycol molecules or hydrophobically modified hydroxyethylcellulose molecules, for reducing the sorption of at least one protein, at least one prostaglandin or at least one prostaglandin analogue on an inner surface of a device.
PCT/FR2012/052079 2011-09-16 2012-09-17 Device for storing and dispensing liquid WO2013038119A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1158281 2011-09-16
FR1158281 2011-09-16

Publications (2)

Publication Number Publication Date
WO2013038119A2 true WO2013038119A2 (en) 2013-03-21
WO2013038119A3 WO2013038119A3 (en) 2015-02-19

Family

ID=47883849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2012/052079 WO2013038119A2 (en) 2011-09-16 2012-09-17 Device for storing and dispensing liquid

Country Status (1)

Country Link
WO (1) WO2013038119A2 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (en) * 1986-10-15 1995-05-24 株式会社大協精工 Stacked syringe stopper
JPH05132065A (en) * 1991-11-05 1993-05-28 Nichiden Rika Glass Hanbai Kk Surface-treated glass bottle
DE19921303C1 (en) * 1999-05-07 2000-10-12 Schott Glas Medical glass container, for holding pharmaceutical or medical diagnostic solution, has an inner PECVD non-stick layer containing silicon, oxygen, carbon and hydrogen
SE0004610D0 (en) * 2000-12-13 2000-12-13 Astrazeneca Ab Surface modification process
GB0117879D0 (en) * 2001-07-21 2001-09-12 Common Services Agency Storage of liquid compositions
EP1640031A3 (en) * 2004-09-28 2006-06-07 Nipro Corporation Syringe coated with lubricant containing silicone oil and silica powder
US8025915B2 (en) * 2006-01-11 2011-09-27 Schott Ag Method of preparing a macromolecule deterrent surface on a pharmaceutical package
US8075995B2 (en) * 2006-03-30 2011-12-13 Becton, Dickinson And Company Coating system, articles and assembly using the same and methods of reducing sticktion

Also Published As

Publication number Publication date
WO2013038119A3 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
EP2575914B1 (en) Functionalized membrane for a chamber for encapsulating cells producing at least one substance of therapeutic interest and bioartificial organ comprising such a membrane
EP0780223B1 (en) Multilayered material, method for producing and applications
EP0687283B1 (en) Elastomeric film comprising droplets, method for preparing same, and uses thereof
Michel et al. Layer-by-layer self-assembled polyelectrolyte multilayers with embedded liposomes: immobilized submicronic reactors for mineralization
FR3001642A1 (en) METHOD FOR SURFACING SURFACES
WO2009095591A1 (en) Method for making patches by electrospray
EP3277234B1 (en) Device for dispensing liquid from a sterile packaging bottle
FR3002745A1 (en) HEART-BARK TYPE PARTICLES BASED ON POLYDOPAMINE AND VEGETABLE OIL
FR3066890A1 (en) USE OF A MATERIAL IN COSMETIC PACKAGINGS AND PRESSURE PRODUCT DELIVERY SYSTEM COMPRISING AT LEAST ONE PART COMPRISING OR INCLUDING SUCH MATERIAL
WO2013038119A2 (en) Device for storing and dispensing liquid
WO2013038120A2 (en) Device for storing and dispensing liquid
FR2954328A1 (en) METHOD FOR SURFACE TREATMENT OF A FLUID PRODUCT DISPENSING DEVICE
WO2017081409A1 (en) Method for treating an elastomer packaging element, and packaging element thus treated
EP2516523B1 (en) Method for treating the surface of a device for dispensing a fluid product
FR3069186B1 (en) FLEXIBLE BARRIER MEMBRANE AND PROCESS FOR PRODUCING THE FLEXIBLE BARRIER MEMBRANE.
FR2954330A1 (en) METHOD FOR SURFACE TREATMENT OF A FLUID PRODUCT DISPENSING DEVICE
EP0695779B1 (en) Process for the surface treatment of articles by sulphonation and neutralisation
EP3661577A2 (en) Coating process
EP4251670A1 (en) Polymer able to form a slippery coating for an ophthalmic injector
FR2663035A1 (en) Process for incorporating an active principle into a membrane and products thus obtained
Gaither et al. Modification of polyurethane to reduce occlusion of enteral feeding tubes
FR3065176B1 (en) DOSING VALVE FOR FLUID PRODUCT DISPENSER
FR3045387A1 (en) COMPOSITION OF HUMAN CONCENTRATED IMMUNOGLOBULINS
GR20200100685A (en) Method for chemical compound immobilization onto solid surfsces employing thermal spraying of powders / heated particles, and gel formation
FR3156676A1 (en) Device for spraying a functional coating of supramolecular structures

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12831784

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12831784

Country of ref document: EP

Kind code of ref document: A2